Edwards Lifesciences Corp EW
We take great care to ensure that the data presented and summarized in this overview for Edwards Lifesciences Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EW
View all-
Vanguard Group Inc Valley Forge, PA62.6MShares$4.35 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY51MShares$3.54 Billion0.11% of portfolio
-
Wellington Management Group LLP Boston, MA31.5MShares$2.19 Billion0.37% of portfolio
-
State Street Corp Boston, MA26.3MShares$1.83 Billion0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA13.5MShares$940 Million0.07% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa9.08MShares$631 Million0.25% of portfolio
-
Jpmorgan Chase & CO New York, NY8.47MShares$589 Million0.05% of portfolio
-
Brown Advisory Inc7.58MShares$527 Million0.65% of portfolio
-
Ninety One Uk LTD London, X07.31MShares$508 Million1.34% of portfolio
-
Alliancebernstein L.P. New York, NY6.98MShares$486 Million0.16% of portfolio
Latest Institutional Activity in EW
Top Purchases
Top Sells
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Insider Transactions at EW
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$325,000
$65.57 P/Share
|
Nov 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
Nov 05
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
25,000
-11.18%
|
$1,625,000
$65.91 P/Share
|
Oct 15
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$345,000
$69.51 P/Share
|
Oct 15
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
Sep 14
2024
|
Wayne Markowitz GM & SVP, Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
648
-6.07%
|
$44,064
$68.52 P/Share
|
Sep 13
2024
|
Andrew M. Dahl SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,920
+38.37%
|
-
|
Sep 11
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$330,000
$66.77 P/Share
|
Sep 11
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
Sep 03
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
5,530
-6.37%
|
$381,570
$69.96 P/Share
|
Sep 03
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
10,910
+11.16%
|
-
|
Aug 20
2024
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
1,250
-4.09%
|
$86,250
$69.95 P/Share
|
Aug 14
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$330,000
$66.08 P/Share
|
Aug 14
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
Jul 11
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
500
-2.11%
|
$47,000
$94.18 P/Share
|
Jul 11
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.07%
|
$22,500
$45.28 P/Share
|
Jul 10
2024
|
David T Feinberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,308
+50.0%
|
-
|
Jul 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$465,000
$93.29 P/Share
|
Jul 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
Jul 07
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.04%
|
$7,544
$92.32 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 171K shares |
---|---|
Exercise of conversion of derivative security | 510K shares |
Open market or private purchase | 580 shares |
Bona fide gift | 7.06K shares |
Payment of exercise price or tax liability | 45.5K shares |
---|---|
Open market or private sale | 501K shares |
Bona fide gift | 7.06K shares |